Impact of COVID-19 on quality of life in survivors with pulmonary sequelae

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10045/141795
Información del item - Informació de l'item - Item information
Título: Impact of COVID-19 on quality of life in survivors with pulmonary sequelae
Autor/es: Rodríguez-Galán, Irene | Albaladejo-Blázquez, Natalia | Ruiz-Robledillo, Nicolás | Pascual-Lledó, José Francisco | Ferrer-Cascales, Rosario | Gil-Carbonell, Joan
Grupo/s de investigación o GITE: Psicología Aplicada a la Salud y Comportamiento Humano (PSYBHE)
Centro, Departamento o Servicio: Universidad de Alicante. Departamento de Psicología de la Salud
Palabras clave: SARS-CoV-2 pneumonia | COVID-19 | Health-related quality of life | Sequelae | Life quality | Pulmonary fibrosis
Fecha de publicación: 22-mar-2024
Editor: Springer Nature
Cita bibliográfica: Scientific Reports. 2024, 14:6926. https://doi.org/10.1038/s41598-024-57603-z
Resumen: SARS-CoV-2 respiratory infection is still under study today, mainly because of its long-term effects. This study aims to analyse health status and health-related quality of life (HRQoL) in survivors of coronavirus pneumonia (COVID-19) who have developed pulmonary sequelae. Prospective observational study of patients diagnosed with COVID-19 pneumonia between February and May 2020. Reviews were conducted at 3 and 12 months after hospital discharge. HRQoL was assessed by administration of the SF-36 questionnaire and data related to medical records and physical examination were also collected. In addition, chest X-ray, computed tomography and pulmonary function test were included as additional tests. 305 patients were admitted for COVID-19 pneumonia of which 130 (42.6%) completed follow-up. The mean age of the enrolled group was 55.9 ± 15.9 years. The most prevalent persistent symptoms were dyspnea (37.3%) and asthenia (36.9%). Pulmonary sequelae were detected in 20.8% of participants. The most frequent alteration was ground ground glass opacities (GGO) (88.9%), with mild extension. Fibrotic changes were found in only 2% of cases. When comparing the two groups, at 3 and 12 months of evolution, lower scores in the vitality (VT) and mental health (MH) domains were found only in the group without sequelae. Days of hospitalisation and Charlson index acted as influential factors on HRQoL. Minimal or mild pulmonary sequelae of SARS-CoV-2 do not cause further deterioration of HRQoL. Repeated medical care and pulmonary rehabilitation are effective tools to improve HRQoL.
URI: http://hdl.handle.net/10045/141795
ISSN: 2045-2322
DOI: 10.1038/s41598-024-57603-z
Idioma: eng
Tipo: info:eu-repo/semantics/article
Derechos: © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Revisión científica: si
Versión del editor: https://doi.org/10.1038/s41598-024-57603-z
Aparece en las colecciones:INV - PSYBHE - Artículos de Revistas

Archivos en este ítem:
Archivos en este ítem:
Archivo Descripción TamañoFormato 
ThumbnailRodriguez-Galan_etal_2024_SciRep.pdf942,66 kBAdobe PDFAbrir Vista previa


Todos los documentos en RUA están protegidos por derechos de autor. Algunos derechos reservados.